1. Were sample sizes chosen to ensure adequate power to detect a pre-specified effect size? If yes, describe methods. If no, write "Not done" in box.
For animal studies, include a statement in the paper about sample size estimate even if no statistical methods were used.
2. How were samples or animals included/excluded from the analysis? Describe inclusion/exclusion criteria and whether they were pre-established.
3. Was a method of randomization used to determine how samples/ animals were allocated to experimental groups and processed? If yes, describe it. If no, write "No randomization" in box.
For animal studies, include a statement in the paper about randomization whether or not randomization was used.
4. Was the investigator blinded to the group allocation during the experiment and/or when assessing outcomes? If yes, state the extent of blinding. If no, write "No blinding" in box.
For animal studies, include a statement about blinding in the paper whether or not blinding was done. 
▸ Figure legends
Each figure legend should contain, for each panel where they are relevant:
• the exact sample size (n) for each experimental group/condition, given as a number, not a range;
• a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.); • a statement of how many times the experiment shown was replicated in the laboratory; We encourage you to include a specific subsection in the methods section for statistics, reagents and animal models. Please note: any boxes left blank or answered "N/A" will be returned to authors for further clarification. In order for the checklist to provide useful information to referees, it is imperative that negative responses to checklist questions are unambiguous (e.g., "irrelevant to experiments" or "no effect size prespecified" or "no blinding was carried out"). To show that antibodies were profiled for use in the system under study (assay and species), provide a citation, catalog number and/or clone number, supplementary information or reference to an antibody validation profile (e.g., Antibodypedia, 1DegreeBio).
▸ Statistics and general methods
7. Identify the source of cell lines and report if they were recently authenticated (e.g., by STR profiling) and tested for mycoplasma contamination.
▸ Animal models 8. Report species, strain, sex and age of animals.
9. For experiments involving live vertebrates, include a statement of compliance with ethical regulations and identify the committee(s) approving the experiments.
10. We recommend consulting the ARRIVE guidelines (PLoS Biol. 8(6), e1000412, 2010) to ensure that other relevant aspects of animal studies are adequately reported.
▸ Human subjects 11. Identify the committee(s) approving the study protocol.
12. Include a statement confirming that informed consent was obtained from all subjects.
13. For publication of patient photos, include a statement confirming that consent to publish was obtained.
14. Report the clinical trial registration number (at ClinicalTrials.gov or equivalent).
15. For phase II and III randomized controlled trials, please refer to the CONSORT statement and submit the CONSORT checklist with your submission.
16. For tumor marker prognostic studies, we recommend that you follow the REMARK reporting guidelines.
▸ Data deposition 17. Provide accession codes for deposited data.
Data deposition in a public repository is mandatory for: a. Protein, DNA and RNA sequences b. Macromolecular structures c. Crystallographic data for small molecules d. Microarray data Deposition is strongly recommended for many other datasets for which structured public repositories exist; more details on our data policy are available here. We encourage the provision of other source data in supplementary information or in unstructured repositories such as Figshare and Dryad.
18. Is computer source code provided with the paper or deposited in a public repository? If so, indicate how it can be obtained.
